ORPH.L Regulatory News (ORPH)

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Senior Management Appointments

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Nigel Trim and Jamie Chorlton as Managing Director and VP Operations respectively, with immediate effect. These are not Board appointments.

Nigel has worked extensively across Europe, CEE and South East Asia in the healthcare industry, spanning over 30 years. A graduate pharmacologist, Nigel brings a wealth of clinical trial expertise to Venn, coupling clinical operations with senior management roles such as sales and marketing. Experienced in M&A, creating and managing growth, he has successfully built and sold several companies and was most recently the European Managing Director of an international CRO.

Jamie brings to Venn 16 years of clinical research experience, gained in CRO, large pharmaceutical and biotech environments. After obtaining a degree in Biomedical Technology, Jamie acquired significant therapeutic expertise, working in both pharmaceutical and medical device clinical trial settings. For the last seven years, Jamie has directed European clinical operations for a global mid-tier CRO and has played a key role in the successful growth of that organisation.

Commenting on the appointments, Venn CEO, Tony Richardson, said: "We see both these appointments as the next step in terms of Venn increasing its profile and operations internationally. We are building a dynamic organisation throughout Europe and we will achieve that through attracting the right people."

Enquiries:

Additional Information:

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.